Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Sao Tome and Principe Health Report.
Press releases published on October 20, 2025
NovaBay Pharmaceuticals, Inc. Regains Compliance with NYSE American Continued Listing Standards
EMERYVILLE, Calif., Oct. 20, 2025 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) ("NovaBay" or the "Company") announces that it has regained compliance with the NYSE American’s continued listing standards. As previously disclosed, …
XORTX Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency
CALGARY, Alberta, Oct. 20, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat …
Healios K.K. to Present at Chardan’s 9th Annual Genetic Medicines Conference
NEW YORK, Oct. 20, 2025 (GLOBE NEWSWIRE) -- HEALIOS K.K. (“Healios”) is pleased to announce that Richard Kincaid, Chief Financial Officer, will present at the Chardan 9th Annual Genetic Medicines Conference in New York City as follows: Date: Tuesday, …
KFSHRC realiza la primera resección robótica de tumor intracraneal en el mundo... Una nueva era en la neurocirugía
RIAD, Arabia Saudita, Oct. 20, 2025 (GLOBE NEWSWIRE) -- En un avance histórico para la medicina robótica, King Faisal Specialist Hospital and Research Centre (KFSHRC) en Riad realizó con éxito la primera resección robótica de tumor intracraneal en el mundo …
KFSHRC Realiza a Primeira Ressecção Robótica de Tumor Intracraniano do Mundo... Uma Nova Era na Neurocirurgia
RIADE, Arábia Saudita, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Em um salto histórico para a medicina robótica, o King Faisal Specialist Hospital and Research Centre (KFSHRC) em Riade realizou com sucesso a primeira ressecção robótica de tumor intracraniano do …
atai Life Sciences Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Common Shares
NEW YORK and AMSTERDAM, Oct. 20, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company focused on transforming the treatment of mental health disorders, today announced that, on October 20, 2025, …
EMS HEALTH LLC Unveils New E-Commerce Platform NuGeneLabs.com for Holistic Wellness
Miami, FL, Oct. 20, 2025 (GLOBE NEWSWIRE) -- EMS HEALTH LLC, a leader in fitness and holistic wellness services, proudly announces the launch of its new e-commerce platform, NuGeneLabs.com. This innovative online store is designed to provide customers with …
BRAVE Trauma Therapist Collective Celebrates 3 Years as Leading Community for Trauma Therapists
HOUSTON, TX, Oct. 20, 2025 (GLOBE NEWSWIRE) -- BRAVE Providers, LLC proudly announces the third anniversary of The BRAVE Trauma Therapist Collective, marking three years of comprehensive support for trauma therapists navigating vicarious trauma, compassion …
Hapbee Announces R&D of Three New Frequency Wellness Signals for Hunger Management, Allergy Comfort, and Sexual Vitality; Closes Private Placement and Appoints Director
VANCOUVER, British Columbia, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Hapbee Technologies Inc. (“Hapbee”), the leading innovator in frequency-based wellness technology, today announced that it is advancing research and development on three new frequency wellness …
Aurora Spine Announces Proposed Warrant Extension
CARLSBAD, Calif., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) (OTCQB: ASAPF), a leader in innovative spine and interventional pain management solutions, today announces that, subject to the …
Bio Usawa Announces Approval of BioUcenta™ by the Rwandan FDA
KIGALI, Rwanda and SAN FRANCISCO, Oct. 20, 2025 (GLOBE NEWSWIRE) -- The Rwanda Food and Drugs Authority has granted market approval for Bio Usawa Biotechnology Ltd.’s (Bio Usawa) BioUcenta™, a biosimilar of Lucentis® (ranibizumab) for the treatment of …
Teva and Prestige Biopharma Enter License Agreement for Tuznue® Commercialization in Europe
Teva and Prestige announce a license and supply agreement for the commercialization of Prestige’s Tuznue®, a biosimilar to Herceptin® (trastuzumab) Tuznue® received European Commission (EC) marketing authorization in September 2024 Partnership brings …
Onco360® Has Been Selected as a Specialty Pharmacy Partner for PHYRAGO™ (dasatinib)
LOUISVILLE, Ky., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Onco360®, the nation’s leading independent specialty pharmacy, has been selected as a pharmacy partner by Cycle Pharmaceuticals Ltd. for Phyrago™ (dasatinib) tablets. Phyrago is a kinase inhibitor …
Lirum Therapeutics Announces FDA “Study May Proceed” Letter Enabling Inclusion of LX-101 in the RAPID Platform Clinical Trial for Ewing Sarcoma and Desmoplastic Small Round Cell Tumor
New York, NY, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Lirum Therapeutics, Inc. (“Lirum”), an innovative clinical-stage biopharmaceutical company focused on the treatment of debilitating diseases, announced today that the U.S. Food and Drug Administration (FDA) …
Health Catalyst to Announce Third Quarter 2025 Operating Results and Host Conference Call on Monday, November 10, 2025
SALT LAKE CITY, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. ("Health Catalyst", Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, will release its third quarter 2025 operating results …
BrightSpring Announces Secondary Offering of Common Stock and Concurrent Share Repurchase
LOUISVILLE, Ky., Oct. 20, 2025 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. (NASDAQ: BTSG) (“BrightSpring” or the “Company”), a leading provider of home and community-based health services for complex populations, today announced that certain of …
Neuphoria Therapeutics Provides Update on AFFIRM-1 Phase 3 Trial Evaluating BNC210 for the Acute Treatment of Social Anxiety Disorder
AFFIRM-1 trial did not meet primary endpoint or secondary endpoints Company to conduct strategic review of portfolio and business operations BURLINGTON, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (Nasdaq: NEUP) (“Neuphoria” or the …
BrightSpring Health Services, Inc. Reports Preliminary Third Quarter 2025 Financial Results and Increases Full Year 2025 Guidance
LOUISVILLE, Ky., Oct. 20, 2025 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. (“BrightSpring” or the “Company”) (NASDAQ: BTSG), a leading provider of home and community-based health services for complex populations, today announced preliminary …
SI-BONE To Report Third Quarter 2025 Financial Results on November 10, 2025
SANTA CLARA, Calif., Oct. 20, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced it will report financial results for the third quarter of 2025 after market close on …
Verrica Pharmaceuticals Receives Positive Feedback from the European Medicines Agency (EMA) Supporting a Clear Regulatory Path Forward to File for Approval of YCANTH® in the European Union
– EMA concludes that the primary endpoint and supportive secondary endpoints from prior successful Phase 3 studies conducted in the U.S. and Japan are adequate to support a filing for the approval of YCANTH® in the EU and that no additional Phase 3 studies …